[HTML][HTML] 21-gene assay to inform chemotherapy benefit in node-positive breast cancer
K Kalinsky, WE Barlow, JR Gralow… - … England Journal of …, 2021 - Mass Medical Soc
Background The recurrence score based on the 21-gene breast-cancer assay has been
clinically useful in predicting a chemotherapy benefit in hormone-receptor–positive, human …
clinically useful in predicting a chemotherapy benefit in hormone-receptor–positive, human …
Oncotype DX Breast Recurrence Score®: A Review of its Use in Early-Stage Breast Cancer
YY Syed - Molecular diagnosis & therapy, 2020 - Springer
Abstract Oncotype DX Breast Recurrence Score® is a 21-gene prognostic and predictive
assay indicated for use in patients with hormone receptor-positive, human epidermal growth …
assay indicated for use in patients with hormone receptor-positive, human epidermal growth …
Is radiomic MRI a feasible alternative to OncotypeDX® recurrence score testing? A systematic review and meta-analysis
Background OncotypeDX® recurrence score (RS) aids therapeutic decision-making in
oestrogen-receptor-positive (ER+) breast cancer. Radiomics is an evolving field that aims to …
oestrogen-receptor-positive (ER+) breast cancer. Radiomics is an evolving field that aims to …
Evaluation oncotype DX® 21‐gene recurrence score and clinicopathological parameters: a single institutional experience
Aims Oncotype DX recurrence score (RS) is a clinically validated assay, which predicts the
likelihood of disease recurrence in oestrogen receptor‐positive/HER2‐negative …
likelihood of disease recurrence in oestrogen receptor‐positive/HER2‐negative …
Radiogenomic signatures of oncotype DX recurrence score enable prediction of survival in estrogen receptor–positive breast cancer: A multicohort study
M Fan, Y Cui, C You, L Liu, Y Gu, W Peng, Q Bai… - Radiology, 2022 - pubs.rsna.org
Background Radiogenomics explores the association between imaging features and
genomic assays to uncover relevant prognostic features; however, the prognostic …
genomic assays to uncover relevant prognostic features; however, the prognostic …
Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base
A Ibraheem, OI Olopade, D Huo - Cancer, 2020 - Wiley Online Library
Background Genomic assays such as Oncotype Dx (ODX) and MammaPrint are used for risk‐
adapted treatment decisions among patients with early breast cancer. However, to the …
adapted treatment decisions among patients with early breast cancer. However, to the …
The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment
K Iles, ML Roberson, P Spanheimer, K Gallagher… - NPJ Breast …, 2022 - nature.com
Oncotype DX (ODX) recurrence score (RS) is a validated tool to guide the use of adjuvant
chemotherapy (AC) in hormone receptor+/HER2-breast cancer. In this analysis, we examine …
chemotherapy (AC) in hormone receptor+/HER2-breast cancer. In this analysis, we examine …
Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter …
Background The Oncotype Dx recurrence score (ODx-RS) guides the adjuvant
chemotherapy decision-making process for patients with early-stage hormone receptor …
chemotherapy decision-making process for patients with early-stage hormone receptor …
Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy
SM Stemmer, M Steiner, S Rizel, N Ben-Baruch… - NPJ Breast …, 2019 - nature.com
Abstract The 21-gene Recurrence Score (RS) assay is a validated prognosticator/predictor
of chemotherapy (CT) benefit in early-stage estrogen receptor (ER)-positive breast cancer …
of chemotherapy (CT) benefit in early-stage estrogen receptor (ER)-positive breast cancer …
The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis
R Weiser, W Haque, E Polychronopoulou… - Breast Cancer Research …, 2021 - Springer
Purpose The 21-gene recurrence score assay (RS) has not been prospectively validated to
predict adjuvant chemotherapy benefit in hormone receptor-positive (HR+), HER2-negative …
predict adjuvant chemotherapy benefit in hormone receptor-positive (HR+), HER2-negative …